The board of directors of China NT Pharma Group Company Limited announced that Mr. Chiu Yu Kang has tendered his resignation as the chief financial officer and the company secretary of the Company with effect from 6 April 2018. Mr. Chiu has also been re-designated as a senior adviser of the Company regarding merger and acquisition issues, to provide advice for acquisitions of the Group. In addition, the Board also announced that Mr. Wang Fei and Mr. Tong Ka Kin Kenneth have been appointed as the Chief Financial Officer and the Company Secretary respectively, with effect from 6 April 2018.

Mr. Wang, aged 41, joined the Company as the Chief Financial Officer with effect from 6 April 2018 and is responsible for the Group's strategic planning, corporate finance activities, overseeing of financial reporting and investor relations matters. Mr. Wang is a Chinese certified public accountant, and has accumulated nearly 20 years of extensive experience in audit, accounting and financial management. Before joining the Company, Mr. Wang worked in AstraZeneca as the chief financial officer of China operation.

He was also an independent director Xinjiang Tianye Co., from March 2013 to October 2016 and a director of Yanchuang Applied Materials (Ganzhou) Inc. Ltd. from October 2016 to November 2017. Mr. Tong, aged 32, joined the Company as the Company secretary with effect from 6 April 2018 and is responsible for company secretarial duties of the Group. Mr. Tong is an associate member of the Hong Kong Institute of Chartered Secretaries and the Institute of Chartered Secretaries and Administrators since 2016.

He has accumulated more than 10 years of experience in audit, accounting and financial management. Before joining the Company, Mr. Tong had worked for various international well-known accounting firms from 2007 to 2016.